Kyverna Therapeutics

1. Kyverna Pipeline RA readout2026Kyverna Pipeline RA readout, 2026, notable
2. Miv-cel MS Ph1 readout2026Miv-cel MS Ph1 readout, 2026, notable
3. Miv-cel (KYV-101) Rheumatoid Arthritis Ph22026Miv-cel (KYV-101) Rheumatoid Arthritis Ph2, 2026, notable
4. KYV-102 corporate update2026KYV-102 corporate update, 2026, routine
5. PMS IIT Ph1 readout2H 2026PMS IIT Ph1 readout, 2H 2026, routine
6. Miv-cel Ph1 readoutAug 2026Miv-cel Ph1 readout, Aug 2026, notable
7. Securities class action filingSep 3, 2026Securities class action filing, Sep 3, 2026, routine
8. Miv-cel BLA filing4Q 2026Miv-cel BLA filing, 4Q 2026, major
9. SPS BLA filing4Q 2026SPS BLA filing, 4Q 2026, notable
10. Oxford Term A Loan corporate4Q 2026Oxford Term A Loan corporate, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.